Neurocrine Biosciences to Participate at Investor Conferences in November
Neurocrine Biosciences (NBIX) has announced its participation in three major investor conferences this November 2024. The company's leadership team will present at the UBS Global Healthcare Conference on November 12 in Rancho Palos Verdes, the Stifel Healthcare Conference on November 18 in New York, and the Jefferies London Healthcare Conference on November 19 in London.
The presentations will be accessible via webcast on Neurocrine's website, with replays available for approximately one month. Neurocrine Biosciences is a neuroscience-focused biopharmaceutical company developing treatments for neurological, neuroendocrine, and neuropsychiatric disorders, with FDA-approved treatments for conditions including tardive dyskinesia and Huntington's disease chorea.
Neurocrine Biosciences (NBIX) ha annunciato la sua partecipazione a tre importanti conferenze per investitori questo novembre 2024. Il team di leadership dell'azienda presenterà alla Conferenza Globale sulla Salute UBS il 12 novembre a Rancho Palos Verdes, alla Conferenza Sanitaria Stifel il 18 novembre a New York e alla Conferenza Sanitaria Jefferies di Londra il 19 novembre a Londra.
Le presentazioni saranno accessibili tramite webcast sul sito web di Neurocrine, con repliche disponibili per circa un mese. Neurocrine Biosciences è un'azienda biofarmaceutica focalizzata sulle neuroscienze, che sviluppa trattamenti per disturbi neurologici, neuroendocrini e neuropsichiatrici, con trattamenti approvati dalla FDA per condizioni come la discinesia tardiva e la chorea di Huntington.
Neurocrine Biosciences (NBIX) ha anunciado su participación en tres importantes conferencias de inversores en noviembre de 2024. El equipo de liderazgo de la empresa presentará en la Conferencia Global de Salud de UBS el 12 de noviembre en Rancho Palos Verdes, en la Conferencia de Salud de Stifel el 18 de noviembre en Nueva York y en la Conferencia de Salud de Jefferies en Londres el 19 de noviembre en Londres.
Las presentaciones estarán disponibles a través de un webcast en el sitio web de Neurocrine, con reposiciones disponibles durante aproximadamente un mes. Neurocrine Biosciences es una empresa biofarmacéutica centrada en las neurociencias, que desarrolla tratamientos para trastornos neurológicos, neuroendocrinos y neuropsiquiátricos, con tratamientos aprobados por la FDA para condiciones como la discinesia tardiva y la corea de Huntington.
Neurocrine Biosciences (NBIX)는 2024년 11월 세 개의 주요 투자자 회의에 참여한다고 발표했습니다. 회사의 경영진은 11월 12일 랜초 팔로스 베르데스에서 열리는 UBS 글로벌 헬스케어 컨퍼런스, 11월 18일 뉴욕에서 열리는 Stifel 헬스케어 컨퍼런스, 11월 19일 런던에서 열리는 Jefferies 런던 헬스케어 컨퍼런스에서 발표할 예정입니다.
발표는 Neurocrine의 웹사이트를 통해 웹캐스트로 제공되며, 리플레이는 약 한 달 동안 이용 가능합니다. Neurocrine Biosciences는 신경과학에 중점을 둔 생명공학 회사로, 신경학적, 내분비 신경, 정신 신경 장애에 대한 치료제를 개발하고 있으며, FDA가 승인한 치료제를 통해 지연성 운동 증상과 헌팅턴병의 무도병 등을 치료하고 있습니다.
Neurocrine Biosciences (NBIX) a annoncé sa participation à trois grandes conférences d'investisseurs en novembre 2024. L'équipe de direction de l'entreprise présentera à la Conférence Mondiale sur la Santé UBS le 12 novembre à Rancho Palos Verdes, à la Conférence Santé Stifel le 18 novembre à New York et à la Conférence Santé Jefferies à Londres le 19 novembre à Londres.
Les présentations seront accessibles via webcast sur le site web de Neurocrine, avec des rediffusions disponibles pendant environ un mois. Neurocrine Biosciences est une entreprise biopharmaceutique axée sur les neurosciences, développant des traitements pour des troubles neurologiques, neuroendocriniens et neuropsychiatriques, avec des traitements approuvés par la FDA pour des conditions telles que la dyskinésie tardive et la chorée de Huntington.
Neurocrine Biosciences (NBIX) hat seine Teilnahme an drei wichtigen Investorenkonferenzen im November 2024 angekündigt. Das Führungsteam des Unternehmens wird am 12. November auf der UBS Global Healthcare Conference in Rancho Palos Verdes, am 18. November auf der Stifel Healthcare Conference in New York und am 19. November auf der Jefferies London Healthcare Conference in London präsentieren.
Die Präsentationen werden über einen Webcast auf der Website von Neurocrine zugänglich sein, mit Übertragungen, die etwa einen Monat lang verfügbar sind. Neurocrine Biosciences ist ein biopharmazeutisches Unternehmen, das sich auf Neurowissenschaften konzentriert und Behandlungen für neurologische, neuroendokrine und neuropsychiatrische Störungen entwickelt, einschließlich von der FDA genehmigter Behandlungen für Zustände wie tardive Dyskinesie und Chorea Huntington.
- None.
- None.
2024 UBS Global Healthcare Conference on November 12
Stifel 2024 Healthcare Conference on November 18
Jefferies London Healthcare Conference on November 19
- Chief Executive Officer Kyle Gano, Chief Financial Officer Matt Abernethy, and Vice-President of Investor Relations Todd Tushla will present at the 2024 UBS Global Healthcare Conference at 1:15 p.m. Pacific Time (4:15 p.m. Eastern Time) on Tuesday November 12, 2024 in
Rancho Palos Verdes, CA. - Chief Financial Officer Matt Abernethy and Chief Commercial Officer Eric Benevich will present at the Stifel 2024 Healthcare Conference at 10:55 a.m. Eastern Time on Monday November 18, 2024 in
New York . - Chief Executive Officer Kyle Gano, Chief Financial Officer Matt Abernethy, and Chief Medical Officer Eiry Roberts will present at the Jefferies London Healthcare Conference at 1:30 p.m. Greenwich Mean Time (8:30 a.m. Eastern Time) on Tuesday November 19, 2024 in
London, United Kingdom .
The live presentations will be webcast and may be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com. A replay of the webcasts will be available on the website approximately one hour after the conclusion of the events and will be archived for approximately one month.
About Neurocrine Biosciences
Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine, and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X (Formerly Twitter) and Facebook. (*in collaboration with AbbVie)
NEUROCRINE BIOSCIENCES, NEUROCRINE, and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc. The Neurocrine logo is a trademark of Neurocrine Biosciences, Inc.
View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-to-participate-at-investor-conferences-in-november-302296896.html
SOURCE Neurocrine Biosciences, Inc.
FAQ
When is Neurocrine Biosciences (NBIX) presenting at the UBS Global Healthcare Conference in 2024?
Which investor conferences is Neurocrine Biosciences (NBIX) attending in November 2024?
How can investors access Neurocrine Biosciences (NBIX) conference presentations in November 2024?
What medical conditions does Neurocrine Biosciences (NBIX) currently have FDA-approved treatments for?
